Respiratory Tract Diseases

568 trials 207 recruiting

Filter these 568 trials by phase, country and sponsor.

Open in Search →

Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis. Ended

2023-510456-23-00 Idiopathic Pulmonary Fibrosis 1 2024-08-14
Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended

2023-504331-41-00 Respiratory tract diseases - Wheezing, Asthma 5 2024-08-02
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
Radiotherapy to enhance the effects of an immune therapy before tumor surgery in patients with advanced non-small cell lung cancer (NSCLC). … Ended

2023-504536-18-00 Resectable, locally advanced non-small cell lung cancer 4 2024-07-31
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab… Ended

2022-502954-15-00 Idiopathic pulmonary fibrosis 4 2024-06-21
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-sm… Ended

2023-508359-38-00 Early-stage Non-squamous Non-small Cell Lung Cancer 5 2024-06-05
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended

2023-509026-21-00 severe asthma 6 2024-06-03
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Chronic Obstructive Pulmonary Disease 5 2024-05-15
Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea… Ended

2023-503385-24-00 Asthma 4 2024-03-12
Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended

2023-504471-25-00 Fibrotic Lung Disease 5 2024-03-01
Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended

2023-504553-12-01 Influenza 6 2023-12-27
ETOP 14-18 CHESS: Immunotherapy, chemotherapy and radiotherapy, followed by surgery or radiotherapy, for patients with newly diagnosed non-s… Ended

2024-511134-12-00 NSCLC, synchronous oligo-metastatic 4 2023-12-20
A Study of Susceptibility to Baloxavir Marboxil in Patients with Influenza and its transmission to their household contacts Ended

2023-504672-22-00 Influenza 5 2023-11-24
Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease Ended

2022-502512-36-00 Progressive Fibrosing Interstitial Lung Diseases 4 2023-10-02
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended

2023-505054-17-00 metastatic TTF-1 negative lung adenocarcinoma 6 2023-09-15
Safe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: a randomized controlled… Ended

2023-504817-56-00 Bronchiolitis 6 2023-09-05
A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended

2022-501352-28-00 Severe community-acquired pneumonia (sCAP) 5 2023-06-07
ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw… Ended

2023-510463-35-00 Patients with KRASG12C-mutant NSCLC, including patients 4 2023-04-26
Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended

2022-502250-14-00 Chronic rhinosinusitis with nasal polyposis 6 2023-04-13
ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w… Ended

2024-512288-29-00 Patients with EGFR-mutant (L858R or del19 only) advance 4 2023-04-11
A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex… Ended

2024-513462-19-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-30
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une… Ended

2024-513460-26-00 Refractory Chronic Cough, Including Unexplained Chronic 5 2023-03-29
A Phase 2a Study to Evaluate the Safety and Efficacy of MK-5475 in Adults With Pulmonary Hypertension Associated with Chronic Obstructive Pu… Ended

2022-501201-13-00 Pulmonary hypertension associated with chronic obstruct 4 2023-03-01